SenzaGen AB
STO: SENZA.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Peter Nahlstedt
- Employees
- 34
- Headquarters
- Lund, Sweden
- IPO year
- 2017
- Market cap
- SEK 184.0M
- Website
- https://senzagen.com
Loading SENZA…
Loading profile data…Frequently asked questions about SENZA
What does SenzaGen AB (SENZA.ST) do?
SenzaGen AB develops, performs, and sells non-animal tests for assessing a substance's allergenicity. The company offers genomic allergen rapid detection (GARD)skin, an in vitro test to identify potential chemical skin sensitizers; GARDpotency, an in vitro add-on test to GARDskin for potency classification; GARDskin Dose-response, an in vitro te...
Where does SENZA.ST trade?
SenzaGen AB (SENZA.ST) trades on the Stockholm Stock Exchange.
What sector is SENZA.ST in?
SenzaGen AB (SENZA.ST) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of SenzaGen AB?
Peter Nahlstedt is the chief executive officer of SenzaGen AB (SENZA.ST).
Where is SenzaGen AB headquartered?
SenzaGen AB is headquartered in Sweden.
Does SENZA.ST pay a dividend?
SenzaGen AB (SENZA.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SENZA.ST go public?
SenzaGen AB (SENZA.ST) completed its initial public offering in 2017.